MUSTANG BIO, INC. Cost of Revenue
MUSTANG BIO, INC. (MBIO) reported Cost of Revenue of $50.00 thousand for the 1-month period ending 2017-05-31, per its 10-K filed 2019-03-18.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2019-03-18
- 2017-05-31: Cost of Goods and Services Sold 1 month $50.00K.
| Period end | Cost of Goods and Services Sold 1 month |
|---|---|
| 2017-05-31 | $50.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |